Welcome to our dedicated page for Envveno Medical Corporation news (Ticker: NVNO), a resource for investors and traders seeking the latest updates and insights on Envveno Medical Corporation stock.
enVVeno Medical Corporation (NASDAQ: NVNO) is an Irvine, California-based, late clinical-stage medical device company developing bioprosthetic, tissue-based venous valves for deep venous disease. This news page aggregates company announcements, press releases, and market disclosures related to enVVeno’s clinical programs, regulatory interactions, and corporate actions.
Readers can follow updates on VenoValve®, enVVeno’s first-in-class surgical replacement venous valve for severe deep chronic venous insufficiency and deep venous insufficiency, as well as enVVe®, its non-surgical, transcatheter-based replacement venous valve for deep venous CVI. News items include information on pivotal clinical studies, health economic analyses, and the company’s discussions with the U.S. Food & Drug Administration, such as the not-approvable letter for the VenoValve PMA application and the subsequent supervisory appeal process.
In addition to clinical and regulatory developments, this feed covers financial and corporate news, including quarterly financial updates, capital-raising arrangements like the at-the-market equity program, and shareholder matters disclosed in proxy statements and Form 8-K filings. Announcements about investor presentations, virtual investor segments, and other outreach events featuring enVVeno’s leadership are also reflected here.
For investors and observers tracking NVNO, the news page offers a centralized view of how enVVeno is progressing its venous valve technologies, responding to regulatory feedback, and managing its capital structure through actions such as a board-approved reverse stock split. Regularly reviewing this page can help users understand the evolving context around enVVeno’s development pipeline, regulatory milestones, and key corporate decisions.
enVVeno Medical Corporation (NASDAQ:NVNO) announced promising results at the 49th Annual VEITH Symposium regarding its VenoValve clinical trial. Three years post-implantation, VenoValve recipients show no relapses of severe Chronic Venous Insufficiency (CVI) or venous ulcers. Average improvements in reflux, CVI manifestations, and pain are stable at 63%, 52%, and 84%, respectively. The trial involved eight patients with an average age of 68. The VenoValve aims to restore proper blood flow in patients with CVI, a condition affecting approximately 2.5 million people in the U.S.
enVVeno Medical Corporation announced the successful preliminary safety review by the FDA for its VenoValve, as part of the ongoing SAVVE U.S. pivotal study. The first 20 patients enrolled showed minimal adverse events, allowing the trial to proceed without changes. Currently, 33 patients are enrolled, with full enrollment expected by Q2 2023. The company reported $42.7 million in cash to sustain operations through 2024, including the upcoming release of pivotal trial data.
enVVeno Medical Corporation (NASDAQ:NVNO) reported its third-quarter 2022 financial results, ending with $42.7 million in cash and investments, providing a runway through 2024. The burn rate was $4.5 million for the quarter. Notably, the company is advancing its SAVVE pivotal trial with strong enrollment and is set to begin the TAVVE first-in-human study in early 2023. However, net losses increased to $6.1 million, up 154% year-over-year, primarily due to higher operating expenses, including a 140% rise in SG&A costs.
enVVeno Medical Corporation (NASDAQ:NVNO) announced CEO Rob Berman will participate in a fireside chat at the Ladenburg Thalmann 2022 Healthcare Conference on September 29, 2022, in New York, NY. Investors can join one-on-one meetings with management. A live video webcast will be available on the Company's website for 90 days post-event. enVVeno specializes in innovative solutions for venous disease, with its lead product, the VenoValve, in pivotal studies and awaiting approval for a non-surgical alternative, enVVe.
enVVeno Medical Corporation (NASDAQ: NVNO) will host a conference call and live audio webcast on September 21, 2022, at 4:30 PM ET. Interested parties can join by calling (877) 407-9708 (domestic) or (201) 689-8259 (international) using conference ID: 13732870. The live webcast will be available on the enVVeno website and archived for 90 days. The company focuses on innovative bioprosthetic solutions for venous disease, with its lead product, the VenoValve, currently in evaluation for treating Chronic Venous Insufficiency.
enVVeno Medical Corporation (Nasdaq: NVNO) announced CEO Robert Berman's participation at the H.C. Wainwright 24th Annual Global Investment Conference in New York from September 12-14, 2022. The event will include virtual one-on-one meetings with investors. A video webcast of the presentation will be live from September 12 at 7:00 AM ET, with a replay available for 90 days on their website. enVVeno focuses on innovative solutions for venous disease, including its lead product, the VenoValve, which is currently evaluated in the SAVVE pivotal study.
enVVeno Medical Corporation (NASDAQ: NVNO) has appointed Kevin Belteau as Vice President of Clinical Operations. Belteau brings over 23 years of experience from Medtronic, where he managed clinical operations for significant studies. enVVeno expects to engage in multiple clinical trials to support the adoption of its VenoValve device, aimed at treating Chronic Venous Insufficiency (CVI). The VenoValve is currently under evaluation in the SAVVE U.S. pivotal trial for safety and effectiveness, addressing a condition affecting around 2.4 million U.S. individuals.
enVVeno Medical Corporation (NASDAQ: NVNO) reported its second quarter results for 2022, ending with $47.2 million in cash and investments, sufficient to fund operations through 2024. The company noted a cash burn of $4.0 million in the quarter, aligning with expectations. However, net losses rose to $7.1 million, a 197% increase due to higher operating expenses. The ongoing SAVVE pivotal trial aims to evaluate the VenoValve for treating Chronic Venous Insufficiency, targeting approximately 2.4 million affected individuals in the U.S.
enVVeno Medical Corporation has announced that the American Medical Association has issued a new CPT III code for the VenoValve, effective January 1, 2023. This code allows for reimbursement for its procedure to treat Chronic Venous Insufficiency (CVI) in the deep veins of the leg, addressing a significant unmet medical need affecting approximately 2.4 million patients in the U.S. The VenoValve is currently under evaluation in the SAVVE U.S. pivotal trial, aiming to restore proper blood flow and alleviate symptoms caused by CVI.
enVVeno Medical Corporation (Nasdaq: NVNO) reported Q1 2022 financial results, ending the quarter with $51.3 million in cash, expected to fund operations through 2024. Their pivotal SAVVE trial is now active with 20 enrolled sites aiming to conclude patient recruitment by Q1 2023 and provide primary data in H2 2023. Despite a 89% rise in net losses to $5.3 million, company plans include unveiling a second device for venous disease in mid-2022, reinforcing their commitment to addressing chronic venous insufficiency affecting approximately 2.4 million Americans.